The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Illumina’s stock closed Wednesday at $84.20 per share, down 32 cents. Its stock value is down about 36% year to date, as the company has also been trying to rebound from its failed $7.1 ...

San Diego-based Illumina is lowering its 2025 guidance to $4.50 adjusted earnings per share, at the low end of the range of $4.50 to $4.65 a share given last month, Chief Financial Officer Ankur ...

Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale.

Illumina announces a new NGS-based spatial technology kit and new software platform, Illumina Connected Multiomics. genprowebdirectory Facebook Linkedin RSS Twitter Youtube ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) on October 23 and set a price target of $252.00. The company’s shares closed yesterday at $141. ...

Illumina Inc., a key player in DNA sequencing and array-based technologies, on Friday that it will establish a Global Capability Center in Bengaluru, India, as an investment to expand its ...

Illumina is getting a new chief financial officer, the latest major leadership change within the past 12 months for the San Diego biotechnology company. Ankur Dhingra will take over as Illumina ...

With a daily gain of 3.15%, a 3-month loss of 8.58%, and a per share loss of 28.53, Illumina Inc (NASDAQ:ILMN) presents a complex picture for value investors. This article seeks to answer the ...

Methods: Illumina SNP microarray data from 13,254 individuals were analyzed with scatterplots and by PennCNV. ... The central cluster is centered in both axes around zero, suggesting “normal” signal ...

San Diego-based Illumina, which specializes in gene sequencing, is appealing an April 3 FTC order that said the company's $7.1 billion acquisition of Grail will curb competition in the cancer ...